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Abstract
Microbial infection urges prompt intervention by the immune system. The complement cascade and neutrophil
granulocytes are the predominant contributors to this immediate anti-microbial action. We have previously shown that
mannan-binding lectin-associated serine protease-1 (MASP-1), the most abundant enzyme of the complement lectin
pathway, can induce p38-MAPK activation, NFkappaB signaling, and Ca2+-mobilization in endothelial cells. Since neutrophil
chemotaxis and transmigration depends on endothelial cell activation, we aimed to explore whether recombinant MASP-1
(rMASP-1) is able to induce cytokine production and subsequent neutrophil chemotaxis in human umbilical vein endothelial
cells (HUVEC). We found that HUVECs activated by rMASP-1 secreted IL-6 and IL-8, but not IL-1alpha, IL-1ra, TNFalpha and
MCP-1. rMASP-1 induced dose-dependent IL-6 and IL-8 production with different kinetics. rMASP-1 triggered IL-6 and IL-8
production was regulated predominantly by the p38-MAPK pathway. Moreover, the supernatant of rMASP-1-stimulated
HUVECs activated the chemotaxis of neutrophil granulocytes as an integrated effect of cytokine production. Our results
implicate that besides initializing the complement lectin pathway, MASP-1 may activate neutrophils indirectly, via the
endothelial cells, which link these effective antimicrobial host defense mechanisms.
Citation: Jani PK, Kajda´csi E, Megyeri M, Dobo´ J, Doleschall Z, et al. (2014) MASP-1 Induces a Unique Cytokine Pattern in Endothelial Cells: A Novel Link between
Complement System and Neutrophil Granulocytes. PLoS ONE 9(1): e87104. doi:10.1371/journal.pone.0087104
Editor: Ger van Zandbergen, Federal Institute for Vaccines and Biomedicines, Germany
Received August 8, 2013; Accepted December 6, 2013; Published January 29, 2014
Copyright:  2014 Jani et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by ‘Janos Bolyai’ Research Fellowship of the Hungarian Academy of Sciences to L.C. (research fellowship number BO/00218/
10, http://mta.hu/osztondijak); and grants No. K100684 (to L.C.), K75084 and K81277 (to E.L.), NK100834 and NK77978 (to P.G.) from The Hungarian Scientific
Research Fund (OTKA, http://www.otka.hu/en); grant No. 206283 (to A.M.) from European Research Council (Starting Independent Investigator, http://erc.europa.
eu). A.M. is also a recipient of International Senior Research Fellowships (087782) of the Wellcome Trust(http://www.wellcome.ac.uk/). K.F. is a recipient of ‘Jedlik
A´nyos’ predoctoral fellowship (TA´MOP 4.2.4.A/1-11-1-2012-0001, http://www.nfu.hu/?lang = en). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jani.peter@med.semmelweis-univ.hu
Introduction
The immune system responds to various pathogens through
different sets of immune mechanisms. The predominant, and most
effective initial mechanisms for eliminating bacterial or fungal
infection are the complement system and neutrophil granulocytes.
The complement system is part of the innate immune system. It
can recognize, identify, and eliminate invading pathogens and
altered host cells. The complement system can be activated
through three different routes: the classical, the lectin, and the
alternative pathways. The pattern-recognition molecules of the
lectin pathway – mannan-binding lectin (MBL), collectin 11 (CL-
K1), and the three ficolins (H-, L-, and M-ficolin) – circulate in the
blood in complexes with MBL-associated serine proteases (MASP-
1, 2 and 3), and mannose-binding lectin associated proteins
(MAp19 and MAp44). When MBL, CL-K1, or ficolins recognize a
microorganism, the activation of MASP-1, as a promiscuous
protease [1], leads to several distinct outcomes: 1) activation of the
complement system via cleavage of MASP-2 [2,3], 2) cleavage of
kininogen and the release of bradykinin [4], 3) cleavage of
fibrinogen and factor XIII (transglutaminase) [5], 4) activation of
endothelial cells via protease activated receptor 4 (PAR-4, a
member of GPCR family) signaling, as we have previously
described [6]. Briefly, we showed that rMASP-1 can cleave
PAR-1, 2, and 4 with different efficacy, and PAR-4 activation
leads to Ca2+-signaling, the nuclear translocation of NFkappaB,
and the phosphorylation of p38-MAPK. The cleavage of
endothelial PAR-1 and PAR-4 by thrombin causes changes in
endothelial cell morphology, as well as in the release of vasoactive
substances and cytokines [7]. In general, cytokine-generation
during the inflammatory response requires the involvement of the
p38-MAPK, JNK, NFkappaB or cAMP responding element-
binding protein (CREB) signaling pathways [8–12].
The endothelium can generate anti-inflammatory cytokines
such as IL-1ra (receptor antagonist), as well as pro-inflammatory
cytokines (e.g. IL-1alpha, IL-6, IL-8, MCP-1 and TNFalpha) in
response to various stimuli [8,10–13]. TNFalpha, IL-1alpha, and
IL-6 are the most important mediators of the acute phase
response, and of fever. Furthermore, TNFalpha can regulate the
levels of the proteins required for antigen presentation. IL-1alpha
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is a regulator of Th1/Th2 balance, whereas IL-6 is a potent
survival factor of plasma cells, and participates in IgA class
switching. IL-1ra is a natural inhibitor of the pro-inflammatory IL-
1beta cytokine [11]. IL-8 and MCP-1 (monocyte chemoattractant
protein) are chemokines, which control the migration of selected
leukocyte subsets into inflamed tissues. IL-8 and MCP-1 are
chemoattractants for neutrophil granulocytes and monocytes,
respectively [14]. IL-6, IL-8 and MCP-1 are secreted with a low
constitutive rate by endothelial cells; however, they can also be
stored in different granular structures (Weibel-Palade bodies and
type-2 chemokine-containing organelles) [15]. Upon pro-inflam-
matory stimuli, both rapid degranulation, and de novo protein
synthesis may result in the elevated secretion of these cytokines.
Although IL-6, IL-8, and MCP-1 are regulated similarly in most
cases, there are also dissimilarities in their secretion. One major
difference is the lacking P-CREB binding site in the promoter
region of MCP-1, but notwithstanding, the expression of IL-6 and
IL-8 can be driven by CREB [9,16–18]. Differential chemokine
production, together with the adhesion molecule pattern, can be
the most important regulators of leukocyte trafficking driven by
the endothelium. The effector function of neutrophil granulocytes
(polymorphonuclear cells, PMN) is a multi-step process. Chemo-
taxis precedes transmigration through endothelial cell junctions,
the production of reactive oxygen species, and microbial killing.
In this study, we described that a unique cytokine profile,
produced by rMASP-1-stimulated HUVECs, is able to induce
chemotaxis of neutrophil granulocytes, as a novel link between the
complement system and the endothelial cell-mediated regulation
of the neutrophil response.
Materials and Methods
Reagents
Recombinant human MASP-1 catalytic fragments (CCP1-
CCP2-SP, abbreviated as rMASP-1) were expressed in E. coli
and prepared according to Dobo´ et al. [1], and Ambrus et al. [19],
respectively. The recombinant enzyme preparations were free of
bacterial contaminations and the effects of rMASP-1 could be
inhibited by C1-Inhibitor as described by Megyeri et al. [6] We
used lyophilized plasma C1-Inhibitor (Berinert P; ZLB Behring),
the natural inhibitor of MASP-1. The specific JNK II inhibitor
(SP600125), the p38-MAPK inhibitor (SB203580), the PI3-Kinase
inhibitor (Wortmannin), the NFkappaB inhibitor (Bay 11-7082),
and the MEK-1/2 inhibitor (U0126) were purchased from
Calbiochem (Merck KGaA, Darmstadt, Germany). Other re-
agents were purchased from Sigma-Aldrich, unless otherwise
stated. All inhibitors were tested and optimized in preliminary
experiments (data not shown).
Preparation and culture of human umbilical vein
endothelial cells (HUVECs)
Cells were harvested from fresh umbilical cords obtained during
normal delivery of healthy neonates (according to Helsinki
Protocol, Semmelweis University Institutional Review Board
specifically approved this study, (permission number: TU-
KEB64/2008), and all participants provided their written
informed consent to participate in this study), by collagenase
digestion as described by Oroszlan et al [20]. HUVECs were kept
in gelatin-precoated flasks in AIM-V medium (Invitrogen)
completed with 1% FCS, 2 ng/ml human recombinant epidermal
growth factor (R&D Systems), 250 pg/ml human recombinant b-
endothelial cell growth factor (BioSource/Invitrogen), and 7.5 U/
ml heparin, hereinafter referred to as Comp-AIM-V. Each
experiment was performed on at least three independent primary
HUVEC cultures from different individuals.
Measurement of CREB phosphorylation by
immunofluorescence microscopy
HUVECs were treated with/without 2 mM of rMASP-1, in
100 ml Comp-AIM-V for 25 minutes, fixed and stained with
rabbit-anti-human phospho-CREB (P-CREB, 1:200, Cell Signal-
ing Technology Inc.) antibody followed by Alexa568 conjugated
goat-anti-rabbit IgG (1:500) and Hoechst 33342 (1:50000,
Molecular Probes/Invitrogen) as described previously [8]. All
analyses were performed using the original, unmodified images;
for visualization, the pictures were modified according to a
standardized procedure, using Adobe Photoshop CS, without
gamma-correction.
Analysis of CREB and JNK phosphorylation by Western
blotting
Confluent cell cultures in 25 cm2 flasks were treated with
rMASP-1, thrombin, TNFalpha or IL-1beta for 25 minutes. After
washing with ice-cold PBS, cells were lysed in buffer containing
30 mM Hepes, pH 7.4, 100 mM NaCl, 1 mM EDTA, 20 mM
NaF, 1 mM PMSF, 1 mM Na3VO4 and 2% protease inhibitor
cocktail (BD Bioscience). For the P-CREB analysis, the buffer
described above was supplemented with 1% Triton-X100.
Samples were separated by 12% SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE), transferred onto PVDF membranes, and
probed as we described previously [8]. For CREB and phospho-
CREB staining, we used the same antibodies as for microscopy.
mRNA analysis
Variously treated HUVECs were lysed and stored in TRIH
reagent. Total RNA purification, reverse transcription and
LightCyclerH analysis were performed as previously described by
Megyeri et al [6]. The primers (Table 1) were designed from NCBI
database, and produced by Bio Basic Canada Inc. GAPDH and b-
actin gene-specific primers were synthesized according to the
published cDNA sequences. The purity and the size of the PCR
products were checked by melting curve analysis and agarose gel-
electrophoresis.
Table 1. The primers used in the qPCR reactions.
interleukin-1 receptor
antagonist
forward: 59-gatacttgcaaggaccaaatgtc-39
reverse: 59-gtctcatcaccagacttgacaca-39
interleukin-1a forward: 59-gcttcctgagcaatgtgaaatac-39
reverse: 59-tgacttataagcacccatgtcaa-39
interleukin-6 forward: 59-ctgcaggacatgacaactcatc-39
reverse: 59-atctgaggtgcccatgctac-3’
interleukin-8 forward: 59-tcctgatttctgcagctctgt-39
reverse: 59-tgtggtccactctcaatcactc-39
monocyte chemoattractant
protein-1
forward: 59-caccaataggaagatctcagtgc-39
reverse: 59-tgagtgttcaagtcttcggagtt-39
tumor necrosis factor-a forward: 59-tgtagcccatgttgtagcaaac-39
reverse: 59-gacctgggagtagatgaggtacag-39
doi:10.1371/journal.pone.0087104.t001
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Measurement of cytokine production by xMAP
technology
Confluent layers (105 cell/well) of HUVECs were cultured onto
96-well plates overnight in 100 ml Comp-AIM-V medium in the
presence of rMASP-1, LPS, IL-1beta and TNFalpha. The optimal
concentration of activators was pre-determined in our previous
studies [6,8,21]. Supernatants were diluted 1:30 (for MCP-1 and
IL-8) or 1:2 (for IL-1alpha, IL-1ra, IL-6 and TNFalpha). The
human Fluorokine MAP Base Kit (PanelA, R&D Systems) was
used according to the manufacturer’s instructions, and measured
in a Luminex 100 reader (Luminex Corporation, Austin, Texas).
Measurement of cytokine production by sandwich ELISA
Confluent layers (105 cell/well) of HUVECs were cultured in
96-well plates for 24 hours in 100 ml Comp-AIM-V medium in the
presence of rMASP-1 or other endothelial cell activating factors.
IL-1alpha, IL-1ra, IL-6, IL-8, MCP-1, and TNFalpha were
measured by sandwich ELISA kits according to the manufacturer’s
protocol (R&D Systems). We also analyzed the production of IL-6
and IL-8 at 1, 3, 6, 10, and 24 hours.
Analysis of IL-6, IL-8 production in presence of pathway
inhibitors
Confluent layers of HUVECs were pre-incubated for 30
minutes with the following pathway inhibitors: SP600125,
25 mM – JNK; SB203580, 2 mM - p38-MAPK; Wortmannin,
100 nM – PI3-K; Bay-11 7082, 5 mM - NFkappaB and U0126,
1 mM - MEK1/2. The effective, non-toxic dose of different
pathway inhibitors was determined in our preliminary experi-
ments, and was similar to the literature data. For rMASP-1
treatment, we used the purified C1-Inhibitor – an endogenous,
irreversible inhibitor of MASP-1 — as negative control. rMASP-1
was pre-incubated with C1-Inhibitor for 30 minutes before
treatment. The IL-6 and IL-8 content of the supernatant were
determined at 3 and 24 hours as described beforehand.
Measurement of rMASP-1 concentration and rMASP-1/
C1-Inhibitor disintegration
We measured the activity of rMASP-1 using LPAPR-AMC
fluorescent substrate as previously described [6]. Concentration of
rMASP-1 was calculated from the slopes of the kinetic curves. The
detection limit of rMASP-1 was 0.5 nM.
In order to assess residual rMASP-1 activity during the assays
on HUVECs, 2 mM rMASP-1 was pre-incubated with or without
equimolar concentration of C1-Inhibitor. Small aliquots were
removed at 0; 0,5; 1; 2; 3; 6; 8 and 24 hours, and tested for specific
rMASP-1 activity.
Neutrophil preparation
Human neutrophils were isolated from venous blood of healthy
volunteers by Ficoll gradient centrifugation, followed by hypotonic
lysis of RBCs [22]. Cells were resuspended in Ca2+/Mg2+-free
HBSS supplemented with 20 mM HEPES, pH 7.4, and used
immediately. All experiments on human neutrophil granulocyte
samples were approved by the institutional review board of
Semmelweis University. All participants provided their written
informed consent to participate in this study.
Preparation of HUVEC supernatants for experiments with
neutrophil granulocytes
To avoid any possible direct effects of rMASP-1 on neutrophil
granulocytes, HUVECs were treated or not with 2 mM rMASP-1
for 30 minutes then the medium was replaced by rMASP-1 free
HBSS containing 0.5 mM CaCl2 and 1 mMMgCl2 for additional
2,5 hours. Then the HBSS supernatants (MASP-SN - rMASP-1
treated HUVEC supernatant, or UNT-SN - untreated HUVEC
supernatant) were collected and stored frozen (280uC) until use.
Superoxide production
To measure reactive oxygen species production, a lucigenin-
based chemiluminescence method was used [23]. Briefly, the cells
were activated with MASP-SN or UNT-SN for 3 hours. In other
experiments, we used HUVEC supernatants as preconditioning
stimuli for 20 minutes and then, the response to 100 mM phorbol
12-myristate 13-acetate (PMA) or 1 mM N-formyl-methionyl-
leucyl-phenylalanine (fMLP) was recorded.
Neutrophil chemotaxis assay
Isolated neutrophils were diluted in assay medium, supplement-
ed with 0.5 mM CaCl2 and 1 mM MgCl2, and then, placed into
Transwell inserts with FCS-coated 3 mm polycarbonate filters
(Corning) essentially as described previously [22,24]. The
Transwell inserts were placed into 24-well plates containing
MASP-SN, UNT-SN or 2 ng/ml IL-8 (Peprotech). Neutrophil
migration over 60 minutes was quantified using an acid
phosphatase assay [24].
Statistical analysis
Data were compared using Student’s t-test or one-way ANOVA
with Tukey’s post-test (GraphPad Prism 5.01 software, GraphPad,
http://www.graphpad.com/). A p-value less than 0.05 was
considered significant. Data are presented as means 6 SEM
unless otherwise stated.
Results
Activation of CREB and JNK by rMASP-1
Previously, we reported that rMASP-1 could activate p38-
MAPK, NFkappaB, and Ca-mobilization in HUVECs. We also
demonstrated that the cleavage of PARs might be the initiator of
rMASP-1 signaling [6]. Since PARs also utilize – through G-
protein coupled signaling – other pathways to induce pro-
inflammatory cytokines, first we examined CREB and JNK
activation by rMASP-1.
We found that rMASP-1 treatment could activate CREB
phosphorylation in HUVECs, compared with untreated cells
(Figure 1/A,B). We confirmed our results by Western Blot
analysis. The effect of rMASP-1 on CREB phosphorylation was
comparable with that of thrombin and of IL-1beta, used as positive
controls. The effect of rMASP-1 could be completely inhibited by
co-incubation with the C1-Inhibitor, which by itself did not induce
CREB phosphorylation (Figure 1/C). rMASP-1 was also able to
induce JNK phosphorylation, and the C1-Inhibitor abolished this
effect too. (Figure 1/D).
Screening of cytokine production
Endothelial cells can produce several pro-, and anti-inflamma-
tory cytokines. Therefore, we treated HUVECs with rMASP-1 for
6 hours and then, determined specific cytokine mRNA levels by
qPCR. The level of IL-1ra, IL-6, IL-8, MCP-1 and TNFalpha
mRNA was increased, whereas the amount of IL-1alpha mRNA
did not change (Figure 2/A). In addition, we treated HUVECs
with rMASP-1 for 24 hours, and measured the cytokine profile
with xMAP technology. IL-6 and IL-8 production increased
significantly. MCP-1 level was moderately, but not significantly
higher than in untreated controls, whereas the production of IL-
1alpha, TNFalpha, IL-1ra did not change (Figure 2/A).
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rMASP-1 dose dependence on IL-6 and IL-8 production
rMASP-1 treatment induced IL-6, and IL-8 production in a
dose-dependent manner. In concentrations as low as 250 nM,
rMASP-1 caused a significant increase in the levels of both
cytokines (one-way ANOVA). Although endothelial cells secrete
large amounts of MCP-1, rMASP-1 did not increase the
production of the latter any further (Figure 2/B-D).
Comparison of rMASP-1 with other endothelial cell
activators
Several internal and external factors can trigger cytokine
production in endothelial cells. A precise comparison of rMASP-
1 with these factors (including fine dose- and time-dependence)
was beyond the scope of our experiments. Nevertheless, we
performed a simple analysis, where the effects of a single, pre-
determined, optimized dose of histamine (50 mM), bradykinin
(20 mM), thrombin (300 nM) [6], TNFalpha (10 ng/mL), IL-1beta
(1 ng/mL), and LPS (100 ng/mL) [8] were compared with those
Figure 1. rMASP-1 treatment of HUVEC activates CREB and JNK signaling pathways. The cells were treated or not treated with 2 mM
rMASP-1 for 25 minutes and then, fixed with ice cold methanol-acetone (1:1), labeled overnight at 4uC with 1:200 diluted rabbit anti-human
Phosopho-CREB antibody, and stained with goat anti-rabbit (1:500) Alexa 568 (left column) and Hoechst nuclear staining (right column). The figure
depicts one out of 5 similar, independent experiments. The bars represent 50 mm (A). The images were obtained by Olympus IX-81 inverted
fluorescence microscope equipped with 406 UPLF objective (NA=0,75), and an Olympus DP70 digital camera. The mean intensity of red
fluorescence in the nuclear and perinuclear region was evaluated using the AnalySIS software. The mean (+/2SEM) differences between the indicated
regions of 5 experiments are shown (B). Cells were seeded on 6-well plates and treated for 25 minutes. Cells were then lysed and Western-blots were
performed. The membranes were probed for CREB and phospho-CREB (C) or JNK and phospho-JNK (D). Two representative phospho-CREB and
phospho-JNK images are shown (linear intensity adjusted). The graphs were calculated from unadjusted values of phospho- and total protein ratios
from 3 independent experiments. The significance of the differences among rMASP-1 and the other treatments is shown. *: p,0.05, **: p,0.01, ***:
p,0.001, ns: non-significant.
doi:10.1371/journal.pone.0087104.g001
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of 2 mM rMASP-1. At 6 hours, rMASP-1 was a less potent inducer
of IL-6 and IL-8 transcripts than IL-1beta or TNFalpha (Figure 3/
A,B), but the effect of histamine was similar. At protein level,
rMASP-1 induced IL-6 more effectively than bradykinin; its
efficacy was similar to that of TNFalpha, histamine, and thrombin,
but inferior to that of IL-1beta, or LPS (Figure 3/C). The effects of
rMASP-1 and TNFalpha on IL-6 production were similar;
however, TNFalpha produced more IL-8 than rMASP-1
(Figure 3/D).
Kinetics of IL-6 and IL-8 production
IL-6 and IL-8 synthesis and secretion are regulated at multiple
levels in endothelial cells. To determine whether the transcription
or the exocytosis of pre-formed granules is the main contributor to
their secretion, we performed kinetic measurements at mRNA and
protein levels. HUVECs were treated with 2 mM rMASP-1, and
samples for mRNA extraction were harvested at 1, 2, 6, and
10 hours. The mRNA level of IL-6 increased rapidly and peaked
between 1 and 2 hours (Figure 4/A). The increase of the mRNA
level of IL-8 was slower (the peak was around 2 hours), but greater
(Figure 4/D). Then, HUVECs were treated with 2 mM rMASP-1,
and supernatants for ELISA were collected at 1, 3, 6, 10, and
24 hours. TNFalpha was used as a positive control. Untreated
HUVECs produced both IL-6 and IL-8 at a basal level. rMASP-1
and TNFalpha induced IL-6 with very similar kinetics (Figure 4/
B,C). The kinetics of IL-8 production was, however, different in
response to rMASP-1 and to TNFalpha. While rMASP-1
promptly induced IL-8 secretion (relative production compared
to untreated cells peaked between 1 and 3 hours), the maximum
effect of TNFalpha was at 6 hours (Figure 4/E,F).
Unraveling the signaling pathways that contribute to IL-6
and IL-8 production induced by rMASP-1
Cytokine production can be triggered through various signaling
pathways, most of which can be activated also by rMASP-1. Thus,
we used several commercially available signaling pathway
inhibitors to identify the most important pathways required for
IL-6 and IL-8 production. HUVECs had been pre-incubated with
the inhibitors for 30 minutes and then, treated with 2 mM rMASP-
1 for 3 or 24 hours. The expression of both IL-6 and IL-8 could be
inhibited by NFkappaB, p38-MAPK, or JNK at 3 hours of
rMASP-1 activation (Figure 5/A,B), whereas only the p38-MAPK
inhibitor was able to block the production of both cytokines
significantly, at 24 hours (Figure 5/C,D). ERK 1/2 and PI3-
kinase inhibitors had no blocking effect at any time. PI3-kinase
inhibitor, however, increased the IL-6 production induced by
rMASP-1 at 3 hours. Furthermore, C1-Inhibitor blocked the
expression of both cytokines when it was pre-incubated with
rMASP-1 for 30 minutes before adding to the cells. Interestingly,
while the blocking effect of the C1-Inhibitor on IL-6 persisted for
24 hours, it had no effect on IL-8 production when applied for
24 hours. Theoretically, this could happen if the rMASP-1/C1-
Inhibitor complex disintegrates within a few hours (unlike C1-
Inhibitor complexed with C1r/s, which is very stable), and
rMASP-1 regains its activity. To test this hypothesis, we explored
the disintegration of the rMASP-1/C1-Inhibitor complex.
rMASP-1 was incubated with or without equimolar amounts of
C1-Inhibitor for 24 hours, and small aliquots were tested with a
fluorometric substrate-cleavage assay at different times. We found
that rMASP-1 enzymatic activity decreased only slightly during
the 24-hour incubation period (initial reaction rates of 20 nM
Figure 2. Screening for cytokine production induced by rMASP-1, and the dose dependence of IL-6, IL-8, and MCP-1. The cells were
treated with 2 mM rMASP-1 for 6 hours (mRNA level) or 24 hours (protein level). Seven cytokines were assessed by qPCR and xMAP technology. (0: no
effect, +: significant induction, (+): tendency for induction, not confirmed by ELISA.) (A) The cells were treated with 0, 0.25, 0.5, 1, 2 mM rMASP-1 for
24 hours, and then, the supernatants were collected. IL-6 (B), IL-8 (C), and MCP-1 (D) production were determined by sandwich ELISA kits according
to the manufacturers’ protocol. The values were calculated as the mean (+/2SEM) of three independent experiments.
doi:10.1371/journal.pone.0087104.g002
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rMASP-1 at 3000 nM substrate concentration: 2314 6 110 pM
substrate/sec to 1863 6 30 pM substrate/sec). The proteolytic
effect of the rMASP-1/C1-Inhibitor complex remained under the
detection limit during the entire experiment.
Activation of neutrophil granulocytes by the supernatant
of rMASP-1 treated HUVECs
Since the advent of high-sensitivity of ELISA assays, the
biological significance of cytokine production can be overestimat-
Figure 3. The comparison of rMASP-1 with other endothelial cell activators. HUVECs were treated with different cell activators (rMASP-1
2 mM, IL-1beta 1 ng/mL, TNFalpha 10 ng/mL, histamine 50 mM, LPS 100 ng/mL, bradykinin 20 mM, thrombin 300 nM) for 6 hours (A, B), or 24 hours
(C, D). mRNA for qPCR (A, B), and the supernatants for ELISA (C, D) were collected and then, IL-6 (A, C) and IL-8 (B, D) expression was determined.
All data are presented as the mean (+/2SEM) of three independent experiments. The significance of the differences among rMASP-1 and other
treatments is shown. *: p,0.05, **: p,0.01, ***: p,0.001, ns: non-significant.
doi:10.1371/journal.pone.0087104.g003
Figure 4. The kinetics of IL-6 and IL-8 production induced by rMASP-1. HUVECs were treated with 2 mM rMASP-1, or with 10 ng/mL TNFa
(only at protein level) for different periods. The samples were analyzed for IL-6 (A, B, C) and IL-8 (D, E, F) by qPCR (A, D) and ELISA (B, C, E, F). qPCR
results were plotted as percentage of non-treated control. The results of ELISA were calculated from the standard curve, and plotted as concentration
values (B, E). To compare the effects of rMASP-1 and of TNFalpha, we calculated the magnitude of the increase of the values (treated/non-treated) at
each time-point (C, F). All data are presented as the mean (+/2SEM) of three independent experiments.
doi:10.1371/journal.pone.0087104.g004
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ed by the statistical methods. Thus, we tested whether the short-
term activation of HUVECs with rMASP-1 was able to induce
cytokines in an amount sufficient to stimulate neutrophil
granulocytes (PMN). To assess the quick response of PMNs, we
monitored superoxide (O2
2) production, and performed chemo-
tactic measurements. To avoid the direct effect of rMASP-1 on
PMNs, media with or without rMASP-1 were replaced after 30
minutes and further incubated in fresh, rMASP-1 free HBSS for
additional 2,5 hours before collection (MASP-SN or UNT-SN,
respectively), as it was described in Materials and Methods, and we
verified that the MASP-SN was rMASP-1 free (Figure 6/A). First,
we assessed superoxide production over 20 minutes by lucigenin-
based chemiluminescence. We found that both supernatants
induced extremely weak O2
2 production, and MASP-SN did
not differ from UNT-SN (1.35% vs. 1.55%, p=0.31, where the
maximal superoxide production, generated by 100 mM PMA, was
regarded as 100%). PMNs were also preconditioned with MASP-
SN or UNT-SN for 20 minutes and then, stimulated with PMA or
fMLP. MASP-SN priming had no effect on the O2
2 generation of
PMNs compared to UNT-SN using either stimulator (15.52% vs.
15.96% for fMLP, p=0.68 and 70.42% vs. 71.13% for PMA,
p=0.76).
Next, we performed a chemotactic assay, where PMNs were
pipetted into transwell inserts and placed into 24-well plates loaded
with HBSS (with Ca2+/Mg2+, as a negative control), MASP-SN,
UNT-SN, or IL-8 (2 ng/mL, as a positive control). Compared
with HBSS, even the untreated HUVEC supernatant induced
chemotaxis, and this was further increased by MASP-SN. The
chemotactic effect of MASP-SN was similar to that of 2 ng/mL
IL-8 (Figure 6/B).
Discussion
We found that rMASP-1 treatment activated JNK and CREB
phosphorylation. The most important pro-inflammatory cytokines
including IL-1beta and TNFalpha can simultaneously activate
different MAPKs and NFkappaB. MASP-1 and these three pro-
inflammatory activators appear to use similar pathways; however,
in case of MASP-1, the MAPK pathways may be more effective
than NFkappaB signaling. CREB, another important transcription
factor of pro-inflammatory cytokine production [9,18,25], can be
phosphorylated and activated via two main routes: by cAMP
activated protein kinase A, and by p38-MAPK [9,26]. Since we
have found previously that p38-MAPK pathway is readily
activated by rMASP-1, the phosphorylation of CREB is not
unexpected [6]. Thrombin, a serine protease similar to MASP-1
[27], also induces CREB phosphorylation, which supports that
PAR signaling can lead to the activation of the CREB
transcription factor [28].
The balance between the pro- and anti-inflammatory pheno-
types is partially dependent on the cytokine pattern produced by
endothelial cells. The pro-inflammatory cytokines IL-1alpha, IL-6,
IL-8, MCP-1 and TNFalpha are representative of the endothelial
phenotypic changes occurring during inflammation [29]. To
counterbalance the effect of pro-inflammatory cytokines, the
endothelium can produce anti-inflammatory cytokines, e.g. IL-
1receptor antagonist, which can downregulate the inflammatory
processes [30]. First, we screened the cytokine pattern of
endothelial cells in response to rMASP-1 by bead-array and
qPCR, to determine the most important targets for future studies.
rMASP-1-triggered endothelial cells produced IL-6 and IL-8 at
mRNA and protein levels, which switched the endothelial cells to a
pro-inflammatory phenotype.
We described that the rMASP-1-induced production of the IL-6
and IL-8 cytokines was dose dependent. Interestingly, although we
showed that rMASP-1 is able to increase the expression of IL-1ra,
MCP-1 and TNFalpha at mRNA level, we could not detect any
dose-dependent production of these chemokines at protein level.
Increased mRNA levels without protein secretion predicts that
MASP-1 may act in synergy with pro-inflammatory factors to
produce IL-1ra, MCP-1 and TNFalpha. MASP-1 is one of the
most abundant proteases in the plasma; its mean systemic
concentration is 11 mg/ml [31] (143 nM). We found that the
measurable effect of rMASP-1 on endothelial cytokine production
was as low as 250 nM. However, at the site of complement
activation and microvessel injury, local MASP-1 concentration
may greatly exceed 143 nM. In these in vivo physiological/
pathophysiological conditions, therefore, MASP-1 concentrations
may be similar to those tested in our in vitro experiments.
One-by-one comparisons of the production of cytokines may be
misleading and useless, because the in vivo concentrations of
endothelial cell activators are different. An alternative approach is
to evaluate complex cytokine patterns [8], focusing on the relative
proportions of the production of individual cytokines. The three
most-cited factors acting as inflammatory signals and triggering
cytokine production by endothelial cells are LPS, TNFalpha, and
IL-1beta [29]. Compared with these, rMASP-1 has a lesser overall
effect on cytokine production, and no effect whatsoever on MCP-1
production, whereas it induces significant IL-6 and IL-8 secretion.
In contrast, LPS, TNFalpha, and IL-1beta stimulate IL-6, IL-8,
and MCP-1 production, although to different extents [8].
Histamine, bradykinin, and thrombin are also well-described
endothelial activators with pro-inflammatory effects, and addi-
tional actions that are not related to the inflammatory process
[32]. Histamine and thrombin induced weak IL-6 and IL-8
expression, and left MCP-1 expression unchanged (data not
shown). Thus, as regards the cytokine pattern, rMASP-1 is more
similar to these two factors than to LPS, IL-1beta, and TNFalpha,
or bradykinin.
Monocyte/granulocyte recruitment occurs at the site of
inflammation within minutes, and the prompt release of relevant
Figure 5. The signaling pathways of IL-6 and IL-8 production
induced by rMASP-1. The cells were pre-incubated with signaling
pathway inhibitors for 30 minutes and then treated with 2 mM rMASP-1
for 3 (A, B) or 24 (C, D) hours. Supernatants were collected and
analyzed with commercial IL-6 (A, C) and IL-8 (B, D) ELISA kits. C1-
Inhibitor (C1Inh) was applied differently; it was premixed with rMASP-1
for 30 minutes and then, the mixture was added to the cells. Each panel
was calculated as the mean (+/2SEM) of 3 independent experiments
using HUVECs from different donors. The significance of the differences
among rMASP-1 and other treatments is shown. *: p,0.05, **: p,0.01.
doi:10.1371/journal.pone.0087104.g005
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mediators from the endothelium underlies this rapid mechanism
[33]. To control the migration of different cell subsets, the
endothelial cells store granules of different cytokine composition
[34]. MCP-1 and IL-8, the two well-characterized chemoattrac-
tants for monocytes and neutrophil granulocytes, are stored
separately, and excreted in different quantities and with dissimilar
velocities [34,35]. The rapid, thrombin-induced secretion of IL-8
takes place without de novo protein synthesis, while the pro-
inflammatory, endothelial activators such as TNFalpha and IL-
1beta cause consistent and prolonged IL-8 production [15,33,35].
IL-6 may co-localize with IL-8, but their separate storage has also
been described [15]. We found that rMASP-1 and TNFalpha
induced similar IL-6 excretion. However, rMASP-1 evoked much
faster release of IL-8 than TNFalpha, and this implicates an
instant chemotactic role for MASP-1-induced endothelial cells in
the early immune response.
To better understand the secretion of cytokines, we tried to
identify the signaling pathways involved in MASP-1-induced IL-6
and IL-8 production. The p38-MAPK inhibitor could abolish IL-6
and IL-8 secretion at both 3 and 24 hours, whereas the NFkappaB
and JNK inhibitors were effective only at 3 hours. The ineffec-
tiveness of JNK and NFkappaB inhibitors at 24 hours could be
explained by the degradation of pathway inhibitors. However,
Cherla et al. showed that these inhibitors were able to block LPS-
induced IL-8 production completely at 24 hours [36]. It implicates
that IL-6/IL-8-containing granules may translocate to Weibel-
Palade bodies (WPBs) and subsequently undergo exocytosis in
response to rMASP-1, as it has been described in case of IL-1beta
[37], and this translocation as well as the process of exocytosis may
be triggered via several pathways [38]. The p38-MAPK pathway,
by contrast, appears to have a major role in the de novo synthesis of
IL-6 and IL-8, which become the predominant cytokines after
24 hours. These cytokines carry several transcription factor-
binding sites at their promoter region, of which NFkappaB, AP-
1 and CREB they share in common. The MCP-1 promoter region
also has binding sites for NFkappaB and AP-1, but not for CREB
[16]. Since rMASP-1 did not induce MCP-1 expression, the
difference in the presence of CREB binding sites between MCP-1
and IL-6/IL-8 promoters may emphasize the importance of
CREB activation in rMASP-1 induced IL-6 and IL-8 production.
PI3-kinase has only a weak effect on rMASP-1 induced IL-6
secretion at 3 hours. It is not surprising that this effect was an
increased cytokine production instead of inhibition because Kim et
al. described that PI3-kinase can suppress the NFkappaB pathway
in HUVECs [39] and we showed that NFkappaB plays a role in
the early IL-6 production by rMASP-1. Unexpectedly, although
the C1-Inhibitor partially blocked IL-6 production at 24 hours, it
had no effect on IL-8 secretion at this time. Since we showed that
the rMASP-1/C1-Inhibitor complex did not disintegrate within
24 hours, an alternative mechanism should be presumed. As the
C1-Inhibitor complex – but not the active C1-Inhibitor – binds to
low-density lipoprotein receptor-related proteins (LRPs) [40]
expressed on endothelial cells [41], it appears plausible that the
rMASP-1/C1-Inhibitor complex may induce IL-8 production via
LRPs after 24 hours of activation.
The differential expression of IL-6/IL-8 and of MCP-1
prompted us to assume that MASP-1-induced endothelial cells
preferentially influence neutrophil functions. Neutrophil granulo-
cytes are the first line of cellular defense against bacterial and
fungal pathogens. Their activation begins within the blood vessels,
whereby chemotaxis is induced by several pro-inflammatory
chemoattractants, including IL-8, fMLP, and C5a [42]. This
rapid process is followed by transmigration, further activation then
phagocytosis and ROS generation. The rMASP-1-induced
HUVEC supernatant did not trigger or prime O2
2 production,
whereas it had a significant effect on the rapid chemotaxis of
neutrophils. Moreover, this effect was similar to that of 2 ng/mL
IL-8, which is nearly the same dose measured in the rMASP-1-
treated HUVEC supernatant.
In our study, we assessed the effects of rMASP-1 on HUVECs
as the most widely used endothelial cell model system. However,
Figure 6. The migration of PMNs activated by the rMASP-1-treated HUVEC supernatant. HUVEC cells were treated with 2 mM rMASP-1, or
left untreated for 30 minutes. Then, the medium was changed to rMASP-1 free HBSS for 2.5 hours and then MASP-SN and UNT-SN were collected.
Residual rMASP-1 concentration of MASP-SN was checked by LPAPR-AMC fluorescent substrate assay, where the Control column shows the rMASP-1
concentration of the rMASP-1 treated HUVEC supernatant before changed to HBSS (A). PMNs were isolated from venous blood collected from 2
healthy volunteers. 10ˆ5 cells were seeded in 3-mm pore size transwell inserts and placed for an hour into the wells containing the MASP-SN, UNT-SN
or HBSS with/without 2 ng/ml IL-8. The percentage of transmigrated/total cells was calculated as the mean (+/2SEM) of 3 different chemotaxis assays
(B). The significance of the differences among rMASP-1 and other treatments is shown. *: p,0.05, ns: non-significant.
doi:10.1371/journal.pone.0087104.g006
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further experiments are required to compare MASP-1 respon-
siveness of endothelial cells with different origin.
MASP-1, a crucial element of the complement lectin pathway
[2], is immediately activated upon microbial infection, enabling
the downstream mediators of the complement system to opsonize
and/or kill microbes. Our findings implicate that rMASP-1 can
promptly attract neutrophil granulocytes by activating endothelial
cells. This action may link the complement lectin pathway to
targeted neutrophil activation, as two highly effective mechanisms
of innate antimicrobial immunity.
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